Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2021 | Developing gingipain inhibitors for the treatment of Alzheimer’s disease

COR388 is an irreversible lysine-gingipain inhibitor currently under investigation in a Phase II/III randomized placebo-controlled trial (GAIN; NCT03823404) for the treatment of Alzheimer’s disease. Michael Detke, MD, PhD, Cortexyme, South San Francisco, CA, discusses COR588, another lysine-gingipain inhibitor soon to enter clinical development. Although working via the same target, COR588 is thought to be longer lasting than COR388, enabling once daily dosing. Clinical development of these agents is ongoing, with several other inhibitors in the pipeline, as well as trials of COR388 in further indications including Parkinson’s disease (PEAK trial). This interview took place during the Alzheimer’s Association International Conference 2021.


Dr Detke is a full-time employee of Cortexyme and has CRTX stock options.